Pubblicazioni

Antineoplastic Effect of ALK Inhibitor Crizotinib in Primary Human Anaplastic Thyroid Cancer Cells with STRN-ALK Fusion In Vitro

2024 - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Ferrari, Silvia Martina; Ragusa, Francesca; Elia, Giusy; Mazzi, Valeria; Balestri, Eugenia; Botrini, Chiara; Rugani, Licia; Patrizio, Armando; Piaggi, Simona; La Motta, Concettina; Ulisse, Salvatore; Virili, Camilla; Antonelli, Alessandro; Fallahi, Poupak

Long-term response to crizotinib in a 17-year-old boy with treatment-naÃ¯ve ALK-positive non-small-cell lung cancer

2022 - CANCER REPORTS

Megaro, Giacomina; Miele, Evelina; Spinelli, Gian Paolo; Alessi, Iside; Del Baldo, Giada; Cozza, Raffaele; Russo, Ida; De Pasquale, Maria Debora; Cefalo, Maria Giuseppina; TomÃ , Paolo; Carai, Andrea; Di Ruscio, Valentina; De Ioris, Maria Antonietta; Mastronuzzi, Angela

Treatment of brain metastases in ALK-positive non-small cell lung cancer

2021 - CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Ceddia, Serena; Codacci-Pisanelli, Giovanni

Comprehensive genomic profiling in large cell neuroendocrine lung cancer: The times they are a-changin'

2021 - RECENTI PROGRESSI IN MEDICINA

Filetti, M.; Piras, M.; Giusti, R.

Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification

2020 - ANNALS OF ONCOLOGY

Mazzotta, M.; Filetti, M.; Rossi, A.; Roberto, M.; Occhipinti, M.; Pernazza, A.; Di Napoli, A.; Scarpino, S.; Vecchione, A.; Giusti, R.; Marchetti, P.

Infantile inflammatory myofibroblastic tumors. Clinicopathological and molecular characterization of 12 cases

2020 - MODERN PATHOLOGY

Lopez-Nunez, O.; John, I.; Panasiti, R. N.; Ranganathan, S.; Santoro, L.; Grelaud, D.; Wu, T.; Buccoliero, A. M.; Casanova, M.; Alaggio, R.; Surrey, L. F.

Role of c-MET inhibitors in overcoming drug resistance in spheroid models of primary human pancreatic cancer and stellate cells

2019 - CANCERS

Firuzi, O.; Che, P. P.; El Hassouni, B.; Buijs, M.; Coppola, S.; LÃ¶hr, M.; Funel, N.; Heuchel, R.; Carnevale, I.; Schmidt, T.; Mantini, G.; Avan, A.; Saso, L.; Peters, G. J.; Giovannetti, E.

Crizotinib plus radiotherapy in brain oligoprogressive NSCLC ROS1 rearranged and PD-L1 strong

2017 - JOURNAL OF THORACIC DISEASE

Occhipinti, M.; Falcone, R.; Onesti, C. E.; Botticelli, A.; Mazzuca, F.; Marchetti, P.; Lauro, S.

Tackling ALK in non-small cell lung cancer: the role of novel inhibitors

2016 - TRANSLATIONAL LUNG CANCER RESEARCH

Facchinetti, F; Tiseo, M; Di Maio, M; Graziano, P; Bria, E; Rossi, G; Novello, S

Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition

2015 - JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Megiorni, Francesca; Mcdowell, Heather P; Camero, Simona; Mannarino, Olga; Ceccarelli, Simona; Paiano, Milena; Losty, Paul D; Pizer, Barry; Shukla, Rajeev; Pizzuti, Antonio; Clerico, Anna; Dominici, Carlo